



PTO/SB/08a (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| <p>Substitute for form 1449/PTO</p> <h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(Use as many sheets as necessary)</p> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 1 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A1* | US-3,450,693 | 06-17-1969 | Suzuki <i>et al.</i> | |
| | A2* | US-3,670,086 | 06-13-1972 | Pryor <i>et al.</i> | |
| | A3* | US-3,692,907 | 09-19-1972 | Fierning <i>et al.</i> | |
| | A4* | US-3,891,660 | 06-24-1975 | Denzel <i>et al.</i> | |
| | A5* | US-3,899,508 | 08-12-1975 | Wikel | |
| | A6* | US-3,917,624 | 11-04-1975 | Abu El-Haj <i>et al.</i> | |
| | A7* | US-4,006,237 | 02-01-1977 | Buckle <i>et al.</i> | |
| | A8* | US-4,053,588 | 10-11-1977 | Konig <i>et al.</i> | |
| | A9* | US-4,381,344 | 04-26-1983 | Rideout <i>et al.</i> | |
| | A10* | US-4,552,874 | 11-12-1985 | Mardin <i>et al.</i> | |
| | A11* | US-4,563,525 | 01-07-1986 | Campbell, Jr. | |
| | A12* | US-4,593,821 | 06-10-1986 | Brule | |
| | A13* | US-4,668,686 | 05-26-1987 | Meanwell <i>et al.</i> | |
| | A14* | US-4,690,930 | 09-01-1987 | Takada <i>et al.</i> | |
| | A15* | US-4,698,346 | 10-06-1987 | Musser <i>et al.</i> | |
| | A16* | US-4,758,574 | 07-19-1988 | Robertson <i>et al.</i> | |
| | A17* | US-4,774,339 | 09-27-1988 | Haugland <i>et al.</i> | |
| | A18* | US-4,775,674 | 10-04-1988 | Meanwell <i>et al.</i> | |
| | A19* | US-4,800,206 | 01-24-1989 | Alig <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B1 | AU-2002239547 | 11-30-2006 | 3m Innovative Properties Co | | |
| | B2 | AU-2004264336-A1 | 02-24-2005 | 3m Innovative Properties Co | | |
| | B3 | CA-2044087-A1 | 12-09-1991 | Roussel Uclaf | | √ |
| | B4 | CA-2158996-A1 | 10-13-1994 | Bayer Ag | | |
| | B5 | CN-1354663-A | 06-19-2002 | 3m Innovative Properties Co | | √ |
| | B6 | EP-0 145 340-A2 | 06-19-1985 | Riker Laboratories Inc | | |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /Nilofar Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 2 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A20* | US-4,826,830 | 05-02-1989 | Han <i>et al.</i> | |
| | A21* | US-4,837,378 | 06-06-1989 | Borgman | |
| | A22* | US-4,880,779 | 11-14-1989 | Gallaher | |
| | A23* | US-4,904,669 | 02-27-1990 | Knoll <i>et al.</i> | |
| | A24* | US-4,988,714 | 01-29-1991 | Alig <i>et al.</i> | |
| | A25* | US-5,187,288 | 02-16-1993 | Kang <i>et al.</i> | |
| | A26* | US-5,225,183 | 07-06-1993 | Purewal <i>et al.</i> | |
| | A27* | US-5,248,782 | 09-28-1993 | Haugland <i>et al.</i> | |
| | A28* | US-5,274,113 | 12-28-1993 | Kang <i>et al.</i> | |
| | A29* | US-5,342,784 | 08-30-1994 | Yamada <i>et al.</i> | |
| | A30* | US-5,352,680 | 10-04-1994 | Portoghese <i>et al.</i> | |
| | A31* | US-5,376,501 | 12-27-1994 | Marien <i>et al.</i> | |
| | A32* | US-5,378,848 | 01-03-1995 | Takada <i>et al.</i> | |
| | A33* | US-5,444,065 | 08-22-1995 | Nikolaides <i>et al.</i> | |
| | A34* | US-5,446,160 | 08-29-1995 | Stucky <i>et al.</i> | |
| | A35* | US-5,494,916 | 02-27-1996 | Lindstrom <i>et al.</i> | |
| | A36* | US-5,500,228 | 03-19-1996 | Lawter <i>et al.</i> | |
| | A37* | US-5,525,612 | 06-11-1996 | Gerster | |
| | A38* | US-5,530,114 | 06-25-1996 | Bennett <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|--|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>) | | | | |
| | B7 | EP-0 223 420-A1 | 05-27-1987 | Shionogi & Co | | |
| | B8 | EP-0 310 950-A1 | 04-12-1989 | Riker Laboratories Inc | | |
| | B9 | EP-0 385 630-A2 | 09-05-1990 | Riker Laboratories Inc | | |
| | B10 | EP-0 389 302-A1 | 09-26-1990 | Riker Laboratories Inc | | |
| | B11 | EP-0 425 306-A2 | 05-02-1991 | Riker Laboratories Inc | | |
| | B12 | EP-0 510 260-A2 | 10-28-1992 | Toyo Jozo Kk | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 3 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A39* | US-5,569,450 | 10-29-1996 | Duan <i>et al.</i> | |
| | A40* | US-5,571,819 | 11-05-1996 | Sabb <i>et al.</i> | |
| | A41* | US-5,578,727 | 11-26-1996 | Andre <i>et al.</i> | |
| | A42* | US-5,585,612 | 12-17-1996 | Harp, Jr. | |
| | A43* | US-5,602,256 | 02-11-1997 | Andre <i>et al.</i> | |
| | A44* | US-5,605,899 | 02-25-1997 | Gerster <i>et al.</i> | |
| | A45* | US-5,612,377 | 03-18-1997 | Crooks <i>et al.</i> | |
| | A46* | US-5,627,281 | 05-06-1997 | Nikolaides <i>et al.</i> | |
| | A47* | US-5,644,063 | 07-01-1997 | Lindstrom <i>et al.</i> | |
| | A48* | US-5,648,516 | 07-15-1997 | Nikolaides <i>et al.</i> | |
| | A49* | US-5,714,608 | 02-03-1998 | Gerster | |
| | A50* | US-5,731,193 | 03-24-1998 | Mori <i>et al.</i> | |
| | A51* | US-5,736,553 | 04-07-1998 | Wick <i>et al.</i> | |
| | A52* | US-5,741,909 | 04-21-1998 | Gerster <i>et al.</i> | |
| | A53* | US-5,750,134 | 05-12-1998 | Scholz <i>et al.</i> | |
| | A54* | US-5,776,432 | 07-07-1998 | Schultz <i>et al.</i> | |
| | A55* | US-5,780,045 | 07-14-1998 | McQuinn <i>et al.</i> | |
| | A56* | US-5,837,809 | 11-17-1998 | Grandy <i>et al.</i> | |
| | A57* | US-5,840,744 | 11-24-1998 | Borgman | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B13 | EP-0 778 277-A1 | 06-11-1997 | Pfizer | | |
| | B14 | EP-0 645 389-A1 | 03-29-1995 | Lonza Ag | | √ |
| | B15 | EP-0 894 797-A1 | 02-03-1999 | Terumo Corp | | |
| | B16 | EP-0 940 629-A2 | 09-08-1999 | Speights Ltd | | |
| | B17 | EP-1 082 960-A2 | 03-14-2001 | Pfizer Prod Inc | | |
| | B18 | EP-1 097 709-A2 | 05-09-2001 | Pfizer Prod Inc | | |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /Nilofar Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 4 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A58* | US-5,854,257 | 12-29-1998 | Armitage <i>et al.</i> | |
| | A59* | US-5,861,268 | 01-19-1999 | Tang <i>et al.</i> | |
| | A60* | US-5,886,006 | 03-23-1999 | Nikolaides <i>et al.</i> | |
| | A61* | US-5,939,047 | 08-17-1999 | Jernberg | |
| | A62* | US-5,962,479 | 10-05-1999 | Chen | |
| | A63* | US-5,962,636 | 10-05-1999 | Bachmaier <i>et al.</i> | |
| | A64* | US-5,977,366 | 11-02-1999 | Gerster <i>et al.</i> | |
| | A65* | US-6,028,076 | 02-22-2000 | Hirota <i>et al.</i> | |
| | A66* | US-6,057,371 | 05-02-2000 | Glennon | |
| | A67* | US-6,069,140 | 05-30-2000 | Sessler <i>et al.</i> | |
| | A68* | US-6,071,949 | 06-06-2000 | Mulshine <i>et al.</i> | |
| | A69* | US-6,077,349 | 06-20-2000 | Kikuchi | |
| | A70* | US-6,113,918 | 09-05-2000 | Johnson <i>et al.</i> | |
| | A71* | US-6,121,323 | 09-19-2000 | Merrill | |
| | A72* | US-6,123,957 | 09-26-2000 | Jernberg | |
| | A73* | US-6,126,938 | 10-03-2000 | Guy <i>et al.</i> | |
| | A74* | US-6,194,388 | 02-27-2001 | Krieg <i>et al.</i> | |
| | A75* | US-6,207,646 | 03-27-2001 | Krieg <i>et al.</i> | |
| | A76* | US-6,239,116 | 05-29-2001 | Krieg <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B19 | EP-1 145 340-A2 | 10-17-2001 | Siemens Westinghouse Power <i>et al.</i> | | |
| | B20 | EP-1 256 582-A1 | 11-13-2002 | Hokuriku Pharmaceutical | | |
| | B21 | EP-1 341 791-A2 | 09-10-2003 | 3m Innovative Properties Co | | |
| | B22 | EP-1 495 758-A2 | 01-12-2005 | 3m Innovative Properties Co | | |
| | B23 | HU-34479-A2 | 03-28-1985 | Egyt Gyogyszervegyeszeti Gyar | | ✓ |
| | B24 | HU-190109-A2 | 03-28-1985 | Egyt Gyogyszervegyeszeti Gyar | | ✓ |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /Nilofar Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|--|---|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 5 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A77* | US-6,294,271 | 09-25-2001 | Sumita <i>et al.</i> | |
| | A78* | US-6,303,347 | 10-16-2001 | Johnson <i>et al.</i> | |
| | A79* | US-6,309,623 | 10-30-2001 | Weers <i>et al.</i> | |
| | A80* | US-6,315,985 | 11-13-2001 | Wu <i>et al.</i> | |
| | A81* | US-6,323,200 | 11-27-2001 | Gerster <i>et al.</i> | |
| | A82* | US-6,329,381 | 12-11-2001 | Kurimoto <i>et al.</i> | |
| | A83* | US-6,339,068 | 01-15-2002 | Krieg <i>et al.</i> | |
| | A84* | US-6,348,462 | 02-19-2002 | Gerster <i>et al.</i> | |
| | A85* | US-6,365,166 | 04-02-2002 | Beaurline <i>et al.</i> | |
| | A86* | US-6,376,501 | 04-23-2002 | Isobe <i>et al.</i> | |
| | A87* | US-6,387,383 | 05-14-2002 | Dow <i>et al.</i> | |
| | A88* | US-6,387,938 | 05-14-2002 | Mizuguchi <i>et al.</i> | |
| | A89* | US-6,406,705 | 06-18-2002 | Davis <i>et al.</i> | |
| | A90* | US-6,426,334 | 07-30-2002 | Agrawal <i>et al.</i> | |
| | A91* | US-6,440,992 | 08-27-2002 | Gerster <i>et al.</i> | |
| | A92* | US-6,451,485 | 09-17-2002 | James <i>et al.</i> | |
| | A93* | US-6,465,654 | 10-15-2002 | Gerster <i>et al.</i> | |
| | A94* | US-6,476,000 | 11-05-2002 | Agrawal | |
| | A95* | US-6,486,168 | 11-26-2002 | Skwierczynski <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B25 | HU-210051-A2 | 06-28-1991 | Riker Laboratories Inc | | |
| | B26 | HU-218950-A2 | 09-28-1995 | Shionogi & Co | | ✓ |
| | B27 | IL-73534-A | 12-23-1990 | Riker Laboratories Inc | | ✓ |
| | B28 | JP-4-066571-A | 03-02-1992 | Meiji Seika Kaisha | | ✓ |
| | B29 | JP-4-327587-A | 11-17-1992 | Asahi Chemical Ind | | ✓ |
| | B30 | JP-5-286973-A | 11-02-1993 | Shionogi & Co | | ✓ |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 6 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A96* | US-6,486,186 | 11-26-2002 | Fowler <i>et al.</i> | |
| | A97* | US-6,511,485 | 01-28-2003 | Hirt <i>et al.</i> | |
| | A98* | US-6,514,985 | 02-04-2003 | Gerster <i>et al.</i> | |
| | A99* | US-6,518,239 | 02-11-2003 | Kuo <i>et al.</i> | |
| | A100* | US-6,518,280 | 02-11-2003 | Gerster <i>et al.</i> | |
| | A101* | US-6,525,028 | 02-25-2003 | Johnson <i>et al.</i> | |
| | A102* | US-6,541,485 | 04-01-2003 | Crooks <i>et al.</i> | |
| | A103* | US-6,582,957 | 06-24-2003 | Turner, Jr. <i>et al.</i> | |
| | A104* | US-6,610,319 | 08-26-2003 | Tomai <i>et al.</i> | |
| | A105* | US-6,627,638 | 09-30-2003 | Gerster <i>et al.</i> | |
| | A106* | US-6,627,639 | 09-30-2003 | Stack <i>et al.</i> | |
| | A107* | US-6,627,640 | 09-30-2003 | Gerster <i>et al.</i> | |
| | A108* | US-6,630,588 | 10-07-2003 | Rice <i>et al.</i> | |
| | A109* | US-6,638,944 | 10-28-2003 | Mickelson | |
| | A110* | US-6,649,172 | 11-18-2003 | Johnson | |
| | A111* | US-6,660,747 | 12-09-2003 | Crooks <i>et al.</i> | |
| | A112* | US-6,677,334 | 01-13-2004 | Gerster <i>et al.</i> | |
| | A113* | US-6,696,076 | 02-24-2004 | Tomai <i>et al.</i> | |
| | A114* | US-6,703,402 | 03-09-2004 | Gerster <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B31 | JP-53-050197-A | 05-08-1978 | Yoshitomi Pharmaceutical | | ✓ |
| | B32 | JP-63-010787-A | 01-18-1988 | Takeda Chemical Industries Ltd | | ✓ |
| | B33 | RU-2076105-C1 | 03-27-1997 | Hoechst Ag | | ✓ |
| | B34 | RU-2127273-C1 | 03-10-1999 | Janssen Pharmaceutica Nv | | ✓ |
| | B35 | RU-2221798-C2 | 01-20-2004 | | | ✓ |
| | B36 | WO-91/06682-A1 | 05-16-1991 | Pfeifer & Langen | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|--|---|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/595,103-Conf. #2609 | |
| | | | Filing Date | February 14, 2006 | |
| | | | First Named Inventor | Kyle J. Lindstrom | |
| | | | Art Unit | 1625 | |
| | | | Examiner Name | N. Rahmani | |
| Sheet | 7 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A115* | US-6,716,988 | 04-06-2004 | Dellaria <i>et al.</i> | |
| | A116* | US-6,720,333 | 04-13-2004 | Dellaria <i>et al.</i> | |
| | A117* | US-6,720,334 | 04-13-2004 | Dellaria <i>et al.</i> | |
| | A118* | US-6,720,422 | 04-13-2004 | Dellaria <i>et al.</i> | |
| | A119* | US-6,780,873 | 08-24-2004 | Crooks <i>et al.</i> | |
| | A120* | US-6,784,188 | 08-31-2004 | Crooks <i>et al.</i> | |
| | A121* | US-6,790,961 | 09-14-2004 | Gerster <i>et al.</i> | |
| | A122* | US-6,800,624 | 10-05-2004 | Crooks <i>et al.</i> | |
| | A123* | US-6,825,350 | 11-30-2004 | Crooks <i>et al.</i> | |
| | A124* | US-6,855,217 | 02-15-2005 | Suzuki | |
| | A125* | US-6,855,350 | 02-15-2005 | Lu | |
| | A126* | US-6,878,719 | 04-12-2005 | Lindstrom <i>et al.</i> | |
| | A127* | US-6,888,000 | 05-03-2005 | Crooks <i>et al.</i> | |
| | A128* | US-6,894,060 | 05-17-2005 | Slade | |
| | A129* | US-6,894,165 | 05-17-2005 | Gerster <i>et al.</i> | |
| | A130* | US-6,897,221 | 05-24-2005 | Crooks <i>et al.</i> | |
| | A131* | US-6,900,016 | 05-31-2005 | Venter <i>et al.</i> | |
| | A132* | US-6,903,113 | 06-07-2005 | Heppner <i>et al.</i> | |
| | A133* | US-6,916,925 | 07-12-2005 | Rice <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B37 | WO-92/01305-A1 | 01-23-1992 | Coloray Display Corp | | |
| | B38 | WO-92/06093-A1 | 04-16-1992 | Minnesota Mining & Mfg | | |
| | B40 | WO-92/15581-A1 | 09-17-1992 | Minnesota Mining & Mfg | | |
| | B41 | WO-92/15582-A1 | 09-17-1992 | Minnesota Mining & Mfg | | |
| | B42 | WO-93/05042-A1 | 03-18-1993 | Minnesota Mining & Mfg | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 8 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A134* | US-6,921,826 | 07-26-2005 | Dellaria <i>et al.</i> | |
| | A135* | US-6,924,293 | 08-02-2005 | Lindstrom | |
| | A136* | US-6,943,240 | 09-13-2005 | Bauer <i>et al.</i> | |
| | A137* | US-6,943,255 | 09-13-2005 | Lindstrom <i>et al.</i> | |
| | A138* | US-6,949,649 | 09-27-2005 | Bonk <i>et al.</i> | |
| | A139* | US-6,953,804 | 10-11-2005 | Dellaria <i>et al.</i> | |
| | A140* | US-6,969,722 | 11-29-2005 | Heppner <i>et al.</i> | |
| | A141* | US-6,989,389 | 01-24-2006 | Heppner <i>et al.</i> | |
| | A142* | US-7,030,129 | 04-18-2006 | Miller <i>et al.</i> | |
| | A143* | US-7,030,131 | 04-18-2006 | Crooks <i>et al.</i> | |
| | A144* | US-7,038,053 | 05-02-2006 | Lindstrom <i>et al.</i> | |
| | A145* | US-7,049,439 | 05-23-2006 | Crooks <i>et al.</i> | |
| | A146* | US-7,078,253 | 07-18-2006 | Brunner <i>et al.</i> | |
| | A147* | US-7,078,523 | 07-18-2006 | Crooks <i>et al.</i> | |
| | A148* | US-7,091,214 | 08-15-2006 | Hays <i>et al.</i> | |
| | A149* | US-7,098,221 | 08-29-2006 | Heppner <i>et al.</i> | |
| | A150* | US-7,112,677 | 09-26-2006 | Griesgraber | |
| | A151* | US-7,115,622 | 10-03-2006 | Crooks <i>et al.</i> | |
| | A152* | US-7,125,890 | 10-24-2006 | Dellaria <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B43 | WO-93/09119-A1 | 05-13-1993 | Minnesota Mining & Mfg | | |
| | B44 | WO-93/20847-A1 | 10-28-1993 | Minnesota Mining & Mfg | | |
| | B45 | WO-94/10171-A1 | 05-11-1994 | Pfizer <i>et al.</i> | | |
| | B46 | WO-95/02597-A1 | 01-26-1995 | Minnesota Mining & Mfg | | |
| | B47 | WO-95/02598-A1 | 01-26-1995 | Minnesota Mining & Mfg | | |
| | B48 | WO-96/11199-A1 | 04-18-1995 | Knoll Ag <i>et al.</i> | | |
| | B49 | WO-96/21663-A1 | 07-18-1996 | Minnesota Mining & Mfg | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|---|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 9 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | A153* | US-7,132,429 | 11-07-2006 | Griesgraber <i>et al.</i> | |
| | A154* | US-7,179,253 | 02-20-2007 | Graham <i>et al.</i> | |
| | A155* | US-7,199,131 | 04-03-2007 | Lindstrom | |
| | A156* | US-7,214,675 | 05-08-2007 | Griesgraber | |
| | A157* | US-7,220,758 | 05-22-2007 | Dellaria <i>et al.</i> | |
| | A158* | US-7,226,928 | 06-05-2007 | Mitra <i>et al.</i> | |
| | A159* | US-7,276,515 | 10-02-2007 | Dellaria <i>et al.</i> | |
| | A160* | US-7,288,550 | 10-30-2007 | Dellaria <i>et al.</i> | |
| | A161* | US-7,375,180 | 05-20-2008 | Gorden <i>et al.</i> | |
| | A162* | US-7,387,271 | 06-17-2008 | Noelle <i>et al.</i> | |
| | A163* | US-7,393,859 | 07-01-2008 | Coleman <i>et al.</i> | |
| | A164* | US-7,427,629 | 09-23-2008 | Kedl <i>et al.</i> | |
| | A165* | US-7,544,697 | 06-09-2009 | Hays <i>et al.</i> | |
| | A166* | US-7,598,382 | 10-06-2009 | Hays <i>et al.</i> | |
| | A167* | US-7,612,083 | 11-03-2009 | Griesgraber | |
| | A168* | US-7,648,997 | 01-19-2010 | Kshirsagar <i>et al.</i> | |
| | A169* | US-2001-0046968 | 11-29-2001 | Zagon <i>et al.</i> | |
| | A170* | US-2002-0137101 | 09-26-2002 | Meyers | |
| | A171* | US-2002-0173655 | 11-21-2002 | Dellaria <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B50 | WO-97/48703-A1 | 12-24-1997 | Minnesota Mining & Mfg | | |
| | B51 | WO-97/48704-A1 | 12-24-1997 | Minnesota Mining & Mfg | | |
| | B52 | WO-98/17279-A1 | 04-30-1998 | Minnesota Mining & Mfg | | |
| | B53 | WO-98/30562-A1 | 07-16-1998 | Terumo Corp <i>et al.</i> | | √ |
| | B54 | WO-98/48805-A1 | 11-05-1998 | Sumitomo Pharma <i>et al.</i> | | |
| | B55 | WO-98/50547-A2 | 11-12-1998 | Schering Corp | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 10 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A172* | US-2002-0193729 | 12-19-2002 | Cormier <i>et al.</i> | |
| | A173* | US-2003-0022302 | 01-30-2003 | Lewis <i>et al.</i> | |
| | A174* | US-2003-0044429 | 03-06-2003 | Aderem <i>et al.</i> | |
| | A175* | US-2003-0082108 | 05-01-2003 | Mulshine <i>et al.</i> | |
| | A176* | US-2003-0088102 | 05-08-2003 | Matsubara <i>et al.</i> | |
| | A177* | US-2003-0096998 | 05-22-2003 | Gerster <i>et al.</i> | |
| | A178* | US-2003-0133733 | 07-17-2003 | Korhonen | |
| | A179* | US-2003-0144283 | 07-31-2003 | Coleman <i>et al.</i> | |
| | A180* | US-2003-0172391 | 09-11-2003 | Turner <i>et al.</i> | |
| | A181* | US-2003-0185835 | 10-02-2003 | Braun | |
| | A182* | US-2003-0199461 | 10-23-2003 | Averett <i>et al.</i> | |
| | A183* | US-2003-0212092 | 11-13-2003 | Heppner <i>et al.</i> | |
| | A184* | US-2003-0216481 | 11-20-2003 | Jia | |
| | A185* | US-2003-0232074 | 12-18-2003 | Lipford <i>et al.</i> | |
| | A186* | US-2003-0232763 | 12-18-2003 | Jia | |
| | A187* | US-2003-0232852 | 12-18-2003 | Lindstrom <i>et al.</i> | |
| | A188* | US-2004-0010007 | 01-15-2004 | Dellaria <i>et al.</i> | |
| | A189* | US-2004-0023870 | 02-05-2004 | Dedera <i>et al.</i> | |
| | A190* | US-2004-0067975 | 04-08-2004 | Crooks <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B56 | WO-98/54226-A1 | 12-03-1998 | Pastoral Agric Res Inst Nz Ltd <i>et al.</i> | | |
| | B57 | WO-99/18105-A1 | 04-15-1999 | Ortho Mcneil Pharm Inc | | |
| | B58 | WO-99/29693-A1 | 06-17-1999 | Minnesota Mining & Mfg | | |
| | B59 | WO-00/06577-A1 | 02-10-2000 | 3m Innovative Properties Co | | |
| | B60 | WO-00/09506-A1 | 02-24-2000 | Hokuriku Pharmaceutical <i>et al.</i> | | v |
| | B61 | WO-00/19987-A1 | 04-13-2000 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 11 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A191* | US-2004-0072858 | 04-15-2004 | Charles <i>et al.</i> | |
| | A192* | US-2004-0076633 | 04-22-2004 | Thomsen <i>et al.</i> | |
| | A193* | US-2004-0092545 | 05-13-2004 | Crooks <i>et al.</i> | |
| | A194* | US-2004-0097542 | 05-20-2004 | Crooks <i>et al.</i> | |
| | A195* | US-2004-0106638 | 06-03-2004 | Lindstrom | |
| | A196* | US-2004-0132748 | 07-08-2004 | Isobe <i>et al.</i> | |
| | A197* | US-2004-0132766 | 07-08-2004 | Griesgraber | |
| | A198* | US-2004-0157874 | 08-12-2004 | Crooks <i>et al.</i> | |
| | A199* | US-2004-0167157 | 08-26-2004 | Masui <i>et al.</i> | |
| | A200* | US-2004-0175336 | 09-09-2004 | Egging <i>et al.</i> | |
| | A201* | US-2004-0204436 | 10-14-2004 | Gerster <i>et al.</i> | |
| | A202* | US-2004-0258698 | 12-23-2004 | Wightman <i>et al.</i> | |
| | A203* | US-2004-0265351 | 12-30-2004 | Miller <i>et al.</i> | |
| | A204* | US-2005-0009858 | 01-13-2005 | Martinez-Colon <i>et al.</i> | |
| | A205* | US-2005-0032829 | 02-10-2005 | Lindstrom <i>et al.</i> | |
| | A206* | US-2005-0048072 | 03-03-2005 | Kedl <i>et al.</i> | |
| | A207* | US-2005-0054640 | 03-10-2005 | Griesgraber <i>et al.</i> | |
| | A208* | US-2005-0054665 | 03-10-2005 | Miller <i>et al.</i> | |
| | A209* | US-2005-0059072 | 03-17-2005 | Birmachu <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B62 | WO-00/40228-A2 | 07-13-2000 | 3m Innovative Properties Co | | |
| | B63 | WO-00/47719-A2 | 08-17-2000 | 3m Innovative Properties Co | | |
| | B64 | WO-00/75304-A1 | 12-14-2000 | Aventis Pasteur <i>et al.</i> | | ✓ |
| | B65 | WO-00/76505-A1 | 12-21-2000 | 3m Innovative Properties Co | | |
| | B66 | WO-00/76518-A1 | 12-21-2000 | 3m Innovative Properties Co | | |
| | B67 | WO-01/34709-A1 | 05-17-2001 | 3m Innovative Properties Co | | |

| | | | |
|-----------------------|-------------------|--------------------|------------|
| Examiner Signature | /Nilofar Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|-------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 12 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|-----------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A210* | US-2005-0070460 | 03-31-2005 | Hammerbeck <i>et al.</i> | |
| | A211* | US-2005-0096259 | 05-05-2005 | Tomai <i>et al.</i> | |
| | A212* | US-2005-0119273 | 06-02-2005 | Lipford <i>et al.</i> | |
| | A213* | US-2005-0136065 | 06-23-2005 | Valiante | |
| | A214* | US-2005-0148620 | 07-07-2005 | Crooks <i>et al.</i> | |
| | A215* | US-2005-0158325 | 07-21-2005 | Hammerbeck <i>et al.</i> | |
| | A216* | US-2005-0171072 | 08-04-2005 | Tomai <i>et al.</i> | |
| | A217* | US-2005-0226878 | 10-13-2005 | Tomai <i>et al.</i> | |
| | A218* | US-2005-0234088 | 10-20-2005 | Griesgraber | |
| | A219* | US-2005-0239733 | 10-27-2005 | Jurk <i>et al.</i> | |
| | A220* | US-2005-0239735 | 10-27-2005 | Miller <i>et al.</i> | |
| | A221* | US-2005-0267145 | 12-01-2005 | Merrill <i>et al.</i> | |
| | A222* | US-2005-0281813 | 12-22-2005 | Dedera <i>et al.</i> | |
| | A223* | US-2006-0009482 | 01-12-2006 | Tomai <i>et al.</i> | |
| | A224* | US-2006-0100229 | 05-11-2006 | Hays <i>et al.</i> | |
| | A225* | US-2006-0106052 | 05-18-2006 | Crooks <i>et al.</i> | |
| | A226* | US-2007-0066639 | 03-22-2007 | Kshirsagar <i>et al.</i> | |
| | A227* | US-2007-0072893 | 03-29-2007 | Krepski <i>et al.</i> | |
| | A228* | US-2007-0099901 | 05-03-2007 | Krepski <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B68 | WO-01/51486-A2 | 07-19-2001 | Byk Gulden Lomberg Chem Fab <i>et al.</i> | | |
| | B69 | WO-01/55439-A1 | 08-02-2001 | Progenics Pharm Inc | | |
| | B70 | WO-01/58900-A1 | 08-16-2001 | Hokuriku Pharmaceutical <i>et al.</i> | | ✓ |
| | B71 | WO-01/74343-A2 | 10-11-2001 | 3m Innovative Properties Co | | |
| | B72 | WO-01/74821-A1 | 10-11-2001 | Shionogi & Co <i>et al.</i> | | ✓ |
| | B73 | WO-02/07725-A1 | 01-31-2002 | Alteon Inc | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 13 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|-----------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A229* | US-2007-0155767 | 07-05-2007 | Radmer <i>et al.</i> | |
| | A230* | US-2007-0167476 | 07-19-2007 | Kshirsagar <i>et al.</i> | |
| | A231* | US-2007-0208052 | 09-06-2007 | Prince <i>et al.</i> | |
| | A232* | US-2007-0213356 | 09-13-2007 | Merrill <i>et al.</i> | |
| | A233* | US-2007-0219196 | 09-20-2007 | Krepski <i>et al.</i> | |
| | A234* | US-2007-0219228 | 09-20-2007 | Niwas <i>et al.</i> | |
| | A235* | US-2007-0259881 | 11-08-2007 | Dellaria <i>et al.</i> | |
| | A236* | US-2007-0259907 | 11-08-2007 | Prince | |
| | A237* | US-2007-0287725 | 12-13-2007 | Miser <i>et al.</i> | |
| | A238* | US-2007-0292456 | 12-20-2007 | Hammerbeck <i>et al.</i> | |
| | A239* | US-2008-0015184 | 01-17-2008 | Kshirsagar <i>et al.</i> | |
| | A240* | US-2008-0070907 | 03-20-2008 | Griesgraber <i>et al.</i> | |
| | A241* | US-2008-0085895 | 04-10-2008 | Griesgraber <i>et al.</i> | |
| | A242* | US-2008-0114019 | 05-15-2008 | Kshirsagar <i>et al.</i> | |
| | A243* | US-2008-0119508 | 05-22-2008 | Slade <i>et al.</i> | |
| | A244* | US-2008-0207674 | 08-28-2008 | Stoesz <i>et al.</i> | |
| | A245* | US-2008-0269192 | 10-30-2008 | Griesgraber <i>et al.</i> | |
| | A246* | US-2008-0306252 | 12-11-2008 | Crooks <i>et al.</i> | |
| | A247* | US-2008-0312434 | 12-18-2008 | Lindstrom <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B74 | WO-02/22809-A2 | 03-21-2002 | Coley Pharm Gmbh <i>et al.</i> | | |
| | B75 | WO-02/24225-A1 | 03-28-2002 | Glaxo Group Ltd <i>et al.</i> | | |
| | B76 | WO-02/46188-A2 | 06-13-2002 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B77 | WO-02/46189-A2 | 06-13-2002 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B78 | WO-02/46190-A2 | 06-13-2002 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B79 | WO-02/46191-A2 | 06-13-2002 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 14 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | A248* | US-2008-0318998 | 12-25-2008 | Prince <i>et al.</i> | |
| | A249* | US-2009-0005371 | 01-01-2009 | Rice <i>et al.</i> | |
| | A250* | US-2009-0017076 | 01-15-2009 | Miller <i>et al.</i> | |
| | A251* | US-2009-0018122 | 01-15-2009 | Lindstrom <i>et al.</i> | |
| | A252* | US-2009-0023722 | 01-22-2009 | Coleman <i>et al.</i> | |
| | A253* | US-2009-0029988 | 01-29-2009 | Kshirsagar <i>et al.</i> | |
| | A254* | US-2009-0030030 | 01-29-2009 | Bonk <i>et al.</i> | |
| | A255* | US-2009-0030031 | 01-29-2009 | Kshirsagar <i>et al.</i> | |
| | A256* | US-2009-0042925 | 02-12-2009 | Kshirsagar <i>et al.</i> | |
| | A257* | US-2009-0062272 | 03-05-2009 | Bonk <i>et al.</i> | |
| | A258* | US-2009-0062328 | 03-05-2009 | Kshirsagar <i>et al.</i> | |
| | A259* | US-2009-0069299 | 03-12-2009 | Merrill <i>et al.</i> | |
| | A260* | US-2009-0069314 | 03-12-2009 | Kshirsagar <i>et al.</i> | |
| | A261* | US-2009-0075980 | 03-19-2009 | Hays <i>et al.</i> | |
| | A262* | US-2009-0099161 | 04-16-2009 | Rice <i>et al.</i> | |
| | A263* | US-2009-0105295 | 04-23-2009 | Kshirsagar <i>et al.</i> | |
| | A264* | US-2009-0124611 | 05-14-2009 | Hays <i>et al.</i> | |
| | A265* | US-2009-0163532 | 06-25-2009 | Perman <i>et al.</i> | |
| | A266* | US-2009-0163533 | 06-25-2009 | Hays <i>et al.</i> | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B80 | WO-02/46192-A2 | 06-13-2002 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B81 | WO-02/85905-A1 | 10-31-2002 | Japan Energy Corp <i>et al.</i> | | ✓ |
| | B82 | WO-03/08421-A1 | 01-30-2003 | Shionogi & Co <i>et al.</i> | | ✓ |
| | B83 | WO-03/09852-A1 | 02-06-2003 | Merck & Co Inc <i>et al.</i> | | |
| | B84 | WO-03/103584-A2 | 12-18-2003 | 3m Innovative Properties Co | | |
| | B85 | WO-03/45494-A2 | 06-05-2003 | Martinez-colon Maria | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 15 | of | 57 | Attorney Docket Number | C1271.70021US02 |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B86 | WO-03/45929-A1 | 06-05-2003 | Takeda Chemical Industries Ltd <i>et al.</i> | | √ |
| | B87 | WO-03/50117-A1 | 06-19-2003 | 3m Innovative Properties Co | | |
| | B88 | WO-03/50118-A1 | 06-19-2003 | 3m Innovative Properties Co | | |
| | B89 | WO-03/50119-A2 | 06-19-2003 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B90 | WO-03/77944-A1 | 09-25-2003 | Glaxo Group Ltd <i>et al.</i> | | |
| | B91 | WO-03/80114-A2 | 10-02-2003 | Powderject Res Ltd <i>et al.</i> | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. *Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| | | | | Attorney Docket Number | C1271.70021US02 |
| Sheet | 18 | of | 57 | | |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | † |
| | | Country Code ² -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B104 | WO-2004/110991-A2 | 12-23-2004 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B105 | WO-2004/110992-A2 | 12-23-2004 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B106 | WO-2005/003064-A2 | 01-13-2005 | 3m Innovative Properties Co | | |
| | B107 | WO-2005/003065-A2 | 01-13-2005 | 3m Innovative Properties Co | | |
| | B108 | WO-2005/016273-A2 | 02-24-2005 | 3m Innovative Properties Co | | |
| | B109 | WO-2005/016275-A2 | 02-24-2005 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Nillofar Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloufar Bahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. *Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

2032211.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| | | | | Attorney Docket Number | C1271.70021US02 |
| Sheet | 21 | of | 57 | | |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B122 | WO-2006/073940-A2 | 07-13-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B123 | WO-2006/074003-A2 | 07-13-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B124 | WO-2006/074045-A2 | 07-13-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B125 | WO-2006/083440-A2 | 08-10-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B126 | WO-2006/084251-A2 | 08-10-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B127 | WO-2006/086449-A2 | 08-17-2006 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| | | | | Attorney Docket Number | C1271.70021US02 |
| Sheet | 22 | of | 57 | | |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|--|-----------------------------------|--|---|---------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | Page Count |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (# known) | | | | |
| | B128 | WO-2006/086633-A2 | 08-17-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B129 | WO-2006/086634-A2 | 08-17-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B130 | WO-2006/091394-A2 | 08-31-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B131 | WO-2006/091567-A2 | 08-31-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B132 | WO-2006/091568-A2 | 08-31-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B133 | WO-2006/091647-A2 | 08-31-2006 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

***EXAMINER:** Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| | | | | Attorney Docket Number | C1271.70021US02 |
| Sheet | 23 | of | 57 | | |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ^o |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B134 | WO-2006/093514-A2 | 09-08-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B135 | WO-2006/098852-A2 | 09-21-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B136 | WO-2006/107753-A2 | 10-12-2006 | 3m Innovative Properties Co | | |
| | B137 | WO-2006/107771-A2 | 10-12-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B138 | WO-2006/107851-A1 | 10-12-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B139 | WO-2006/107853-A2 | 10-12-2006 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| | | | | Attorney Docket Number | C1271.70021US02 |
| Sheet | 24 | of | 57 | | |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T ⁶ |
| | | Country Code ² -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | B140 | WO-2006/121528-A2 | 11-16-2006 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B141 | WO-2006/122806-A2 | 11-23-2006 | Novartis Ag <i>et al.</i> | | |
| | B142 | WO-2007/028129-A1 | 03-08-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B143 | WO-2007/030775-A2 | 03-15-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B144 | WO-2007/030777-A2 | 03-15-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B145 | WO-2007/035935-A1 | 03-29-2007 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Bahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | | |
|-------|----|----|----|
| Sheet | 25 | of | 57 |
|-------|----|----|----|

Complete if Known

| | |
|--------------------|------------------------|
| Application Number | 10/595,103-Conf. #2609 |
|--------------------|------------------------|

| | |
|-------------|-------------------|
| Filing Date | February 14, 2006 |
|-------------|-------------------|

| | |
|----------------------|-------------------|
| First Named Inventor | Kyle J. Lindstrom |
|----------------------|-------------------|

| | |
|----------|------|
| Art Unit | 1625 |
|----------|------|

| | |
|---------------|------------|
| Examiner Name | N. Rahmani |
|---------------|------------|

| | |
|------------------------|-----------------|
| Attorney Docket Number | C1271.70021US02 |
|------------------------|-----------------|

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | †6 |
|--------------------|-----------------------|--|--------------------------------|---|---|----|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (# known) | | | | |
| | B146 | WO-2007/056112-A2 | 05-18-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B147 | WO-2007/062043-A1 | 05-31-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B148 | WO-2007/075468-A1 | 07-05-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B149 | WO-2007/079086-A1 | 07-12-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B150 | WO-2007/079146-A1 | 07-12-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B151 | WO-2007/079169-A2 | 07-12-2007 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Substitute for form 1449/PTO

(Use as many sheets as necessary)

| | | | |
|-------|----|----|----|
| Sheet | 26 | of | 57 |
|-------|----|----|----|

Complete if Known

| | |
|------------------------|------------------------|
| Application Number | 10/595,103-Conf. #2609 |
| Filing Date | February 14, 2006 |
| First Named Inventor | Kyle J. Lindstrom |
| Art Unit | 1625 |
| Examiner Name | N. Rahmani |
| Attorney Docket Number | C1271.70021US02 |

[illegible]

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | Page Count |
|--------------------|-----------------------|--|--------------------------------|---|---|------------|
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (# known) | | | | |
| | B152 | WO-2007/079171-A2 | 07-12-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B153 | WO-2007/079202-A2 | 07-12-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B154 | WO-2007/079203-A2 | 07-12-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B155 | WO-2007/092641-A2 | 08-16-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B156 | WO-2007/106852-A2 | 09-20-2007 | 3m Innovative Properties Co <i>et al.</i> | | |
| | B157 | WO-2007/106854-A2 | 09-20-2007 | 3m Innovative Properties Co <i>et al.</i> | | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

2032211.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| | | | | Attorney Docket Number | C1271.70021US02 |
| Sheet | 27 | of | 57 | | |

[illegible]

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|---------------------|--|---|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear | T |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | MM-DD-YYYY | | | |
| | B158 | WO-2007/120121-A2 | 10-25-2007 | Coley Pharm Group Inc <i>et al.</i> | | |
| | B159 | WO-2007/143526-A2 | 12-13-2007 | Coley Pharm Group Inc <i>et al.</i> | | |
| | B160 | WO-2008/008432-A2 | 01-17-2008 | Coley Pharm Group Inc <i>et al.</i> | | |
| | B161 | WO-2008/030511-A2 | 03-13-2008 | Coley Pharmaceutical Group In <i>et al.</i> | | |
| | B162 | WO-2008/036312-A1 | 03-27-2008 | Coley Pharm Group Inc <i>et al.</i> | | |
| | B163 | WO-2008/045543-A1 | 04-17-2008 | Coley Pharm Group Inc <i>et al.</i> | | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Nilofar Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|-------------------|-----------------|------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(ii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 28 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C1 | [NO AUTHOR LISTED] "Comparative Tests." Filed April 8, 2005 during prosecution for EP 00938205.2, EP 00950215.4 and EP 00938211.0 in the name of 3M Innovative Properties Co. | |
| | C2 | [NO AUTHOR LISTED] Chemical Abstracts. 1964;61(1):6060g. | |
| | C3 | [NO AUTHOR LISTED] Encyclopedia of Pharmaceutical Technology. 2nd Ed. Marcel Dekker, Inc. 2002:856-60. | |
| | C4 | AGRAWAL <i>et al.</i> , Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem Soc Trans. 2007 Dec;35(Pt 6):1461-7. | |
| | C5 | AHMED <i>et al.</i> , A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J Immunol Methods. 1994 Apr 15;170(2):211-24. | |
| | C6 | AKIRA <i>et al.</i> , Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett. 2003;85:85-95. | |
| | C7 | AKIRA <i>et al.</i> , Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunol. 2001;2(8):675-80 | |
| | C8 | ALEXOPOULOU <i>et al.</i> , Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature. 2001 Oct 18;413(6857):732-8. | |
| | C9 | ASSUMA <i>et al.</i> , IL-1 and TNF Antagonists Inhibit the Inflammatory Response and Bone Loss in Experimental Periodontitis. J Immunol. 2000;160:403-09. | |
| | C10 | AU <i>et al.</i> , Virus-mediated induction of interferon A gene requires cooperation between multiple binding factors in the interferon alpha promoter region. J Biol Chem. 1993 Nov 15;268(32):24032-40. | |

| | | | |
|-----------------------|---------------------|--------------------|------------|
| Examiner Signature | /Nilloofar Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|---------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Complete if Known | | |
| | | | Application Number | 10/595,103-Conf. #2609 | |
| | | | Filing Date | February 14, 2006 | |
| | | | First Named Inventor | Kyle J. Lindstrom | |
| | | | Art Unit | 1625 | |
| | | | Examiner Name | N. Rahmani | |
| Sheet | 29 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C11 | AUERBACH <i>et al.</i> , Erythema nodosum following a jellyfish sting. J Emerg Med. 1987 Nov-Dec;5(6):487-91. | |
| | C12 | AUWERS, [Über die Isomerie-Verhältnisse in der Pyrazol-Reihe. Berichte. VI.] 1926;601-607. German | |
| | C13 | BAFFIS <i>et al.</i> , Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med. 1999 Nov 2;131(9):696-701. | |
| | C14 | BAKER <i>et al.</i> , Oral infection with Porphyromonas gingivalis and induced alveolar bone loss in immunocompetent and severe combined immunodeficient mice. Arch Oral Biol. 1994 Dec;39(12):1035-40. | |
| | C15 | BALDWIN <i>et al.</i> , Amino Acid Synthesis via Ring Opening of N-Sulphonyl Aziridine-2-Carboxylate Esters with Organometallic Reagents. Tetrahedron. 1993;49:6309-30. | |
| | C16 | BÁRTOVÁ <i>et al.</i> , Th1 and Th2 cytokine profile in patients with early onset periodontitis and their healthy siblings. Mediators Inflamm. 2000;9(2):115-20. | |
| | C17 | BECK <i>et al.</i> , Dental Infections and Atherosclerosis. Am Heart J. 1999;13:528-33. | |
| | C18 | BECKETT <i>et al.</i> , Configurational Studies in Synthetic Analgesics: the Synthesis of (-)-Methadone from D-(-)- Alanine. J Chem Soc. 1957;1:858-61. | |
| | C19 | BEILMAN <i>et al.</i> , Experimental brown spider bite in the guinea pig: Results of treatment with dapsone or hyperbaric oxygen. J Wilderness Medicine. 1994;5:287-94. | |
| | C20 | BELIKOV, Abbreviated Guide to Synthetic and Natural Medications. Pharmaceutical Chemistry. Higher School. 1993;1:43-47. Russian. | ✓ |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Bahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 30 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C21 | BELTRAMI <i>et al.</i> , Some Methylhydrazonium Salts; An Improved Synthesis of Tetramethylhydrazine. J Am Chem Soc. 1956;1956:2467-68. | |
| | C22 | BERNSTEIN <i>et al.</i> , Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment. J Infect Dis. 2001 Mar 15;183(6):844-9. Epub 2001 Feb 13. | |
| | C23 | BERTINO <i>et al.</i> , Principles of Cancer Therapy. Cecil Textbook of Medicine. Goldman <i>et al.</i> , eds. 21th Ed. W.B. Saunders Company. 2000:1:1060-74. | |
| | C24 | BEUTLER <i>et al.</i> , Tumor necrosis factor in the pathogenesis of infectious diseases. Crit Care Med. 1993 Oct;21(10 Suppl):S423-35. | |
| | C25 | BEUTNER <i>et al.</i> , Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol. 1999 Dec;41(6):1002-7. | |
| | C26 | BEUTNER <i>et al.</i> , Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):230-9. | |
| | C27 | BINDER, Acute arthropod envenomation. Incidence, clinical features and management. Med Toxicol Adverse Drug Exp. 1989 May-Jun;4(3):163-73. | |
| | C28 | BISHOP <i>et al.</i> , Molecular mechanisms of B lymphocyte activation by the immune response modifier R-848. J Immunol. 2000 Nov 15;165(10):5552-7. | |
| | C29 | BITTERMAN-DEUTSCH <i>et al.</i> , [Brown spider bite]. Harefuah. 1990 Sep;119(5-6):137-9. Hebrew. | ✓ |
| | C30 | BOOTH <i>et al.</i> , Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol. 1992 Feb;98(2):135-40. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 31 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C31 | BORKAN <i>et al.</i> , An outbreak of venomous spider bites in a citrus grove. Am J Trop Med Hyg. 1995 Mar;52(3):228-30. | |
| | C32 | BOURKE <i>et al.</i> , The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003 Aug 1;102(3):956-63. Epub 2003 Apr 10. | |
| | C33 | BRANTS, The Distribution of Tobacco Mosaic Virus (TMV) in Excised Tomato Roots Cultivated in Vitro. Tijdschr Plantenziekten, 1962;68:198-207. | |
| | C34 | BRASSARD <i>et al.</i> , Interferon- α as an immunotherapeutic protein. J Leukoc Biol. 2002 Apr;71(4):565-81. | |
| | C35 | BREATHNACH, Azelaic acid: potential as a general antitumoural agent. Med Hypotheses. 1999 Mar;52(3):221-6. | |
| | C36 | BROUGHTON, Management of the brown recluse spider bite to the glans penis. Mil Med. 1996 Oct;161(10):627-9. | |
| | C37 | BUCKLE <i>et al.</i> , 4-hydroxy-3-nitro-2-quinolones and related compounds as inhibitors of allergic reactions. J Med Chem. 1975 Jul;18(7):726-32. | |
| | C38 | BUISSON <i>et al.</i> , Preparation and use of (S)-O-acetyllactyl chloride (Mosandl's reagent) as a chiral derivatizing agent. Tetrahedron Assym. 1999;10:2997-3002. | |
| | C39 | BULUT <i>et al.</i> , Cooperation of Toll-like receptor 2 and 6 for cellular activation by soluble tuberculosis factor and Borrelia burgdorferi outer surface protein A lipoprotein: role of Toll-interacting protein and IL-1 receptor signaling molecules in Toll-like receptor 2 signaling. J Immunol. 2001 Jul 15;167(2):987-94. | |
| | C40 | BURLESON, Chapter 14. Influenza Virus Host Resistance Model for Assessment of Immunostimulation, and Antiviral Compounds. Methods in Immunology. 1995;2:181-202. | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Nilofar Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 32 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C41 | BUSCHLE <i>et al.</i> , Interferon γ inhibits apoptotic cell death in B cell chronic lymphocytic leukemia. J Exp Med. 1993 Jan 1;177(1):213-8. | |
| | C42 | CAI <i>et al.</i> , Evaluation of trifluoroacetic acid as an ion-pair reagent in the separation of small ionizable molecules by reversed-phase liquid chromatography. Analytica Chimica Acta. 1999;399:249-258 | |
| | C43 | CANTELL <i>et al.</i> , IFN- γ Enhances Production of IFN- α in Human Macrophages but Not in Monocytes. J Interferon and Cytokine Res. 1996;16:461-63. | |
| | C44 | CARCELLER <i>et al.</i> , Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists. J Med Chem. 1996 Jan 19;39(2):487-93. | |
| | C45 | CARRIGAN <i>et al.</i> , Synthesis and in vitro pharmacology of substituted quinoline-2,4-dicarboxylic acids as inhibitors of vesicular glutamate transport. J Med Chem. 2002 May 23;45(11):2260-76. | |
| | C46 | CATARZI <i>et al.</i> , Tricyclic heteroaromatic systems. Pyrazolo[3,4-c]quinolin-4-ones and pyrazolo[3,4-c]quinoline-1,4-diones: synthesis and benzodiazepine receptor activity. Arch Pharm (Weinheim). 1997 Dec;330(12):383-6. | |
| | C47 | CHESON <i>et al.</i> , National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996 Jun 15;87(12):4990-7. | |
| | C48 | CHUANG <i>et al.</i> , Toll-like receptor 9 mediates CpG-DNA signaling. J Leukoc Biol. 2002 Mar;71(3):538-44. | |
| | C49 | CLAISEN, [Uber α -Methyl-isoxazol.] Berichte. 1909;42:59-69. German. | |
| | C50 | COHEN <i>et al.</i> , Cytokine function: a study in biologic diversity. Am J Clin Pathol. 1996 May;105(5):589-98. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 33 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | | |
|---------------------------------|-----------------------|---|----------------|--|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | C51 | COLE <i>et al.</i> , Brown recluse spider envenomation of the eyelid: an animal model. Ophthal Plast Reconstr Surg. 1995 Sep;11(3):153-64. | | |
| | C52 | COLOTTA <i>et al.</i> , Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists. J Med Chem. 2000 Aug 10;43(16):3118-24. | | |
| | C53 | CRISTALLI <i>et al.</i> , Adenosine deaminase inhibitors: synthesis and structure-activity relationships of imidazole analogues of erythro-9-(2-hydroxy-3-nonyl)adenine. J Med Chem. 1991 Mar;34(3):1187-92. | | |
| | C54 | DAI <i>et al.</i> , Synthesis of a novel C2-symmetric thiourea and its application in the Pd-catalyzed cross-coupling reactions with arenediazonium salts under aerobic conditions. Org Lett. 2004 Jan 22;6(2):221-4. | | |
| | C55 | DAVIS, Current therapy for chronic hepatitis C. Gastroenterology. 2000 Feb;118(2 Suppl 1):S104-14. | | |
| | C56 | DAVIS <i>et al.</i> , Heterocyclic Syntheses with Malonyl Chloride. Part VI. 3-Substituted Pyridine Derivatives from α -Methylene-nitriles. J Chem Soc. 1962:3638-44. | | |
| | C57 | DAVIS <i>et al.</i> , Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases. J Reprod Med. 2000 Aug;45(8):619-23. | | |
| | C58 | DE CLERQ, Synthetic interferon inducers. Top Curr Chem. 1974;52:173-208. | | |
| | C59 | DE <i>et al.</i> , Structure-activity relationships for antiparasitic activity among 7-substituted 4-aminoquinolines. J Med Chem. 1998 Dec 3;41(25):4918-26. | | |
| | C60 | DEBOL <i>et al.</i> , Anti-inflammatory action of dapson: inhibition of neutrophil adherence is associated with inhibition of chemoattractant-induced signal transduction. J Leukoc Biol. 1997 Dec;62(6):827-36. | | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 34 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C61 | DECKER <i>et al.</i> , Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. <i>Blood</i> . 2000 Feb 1;95(3):999-1006. | |
| | C62 | DECKER <i>et al.</i> , Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype. <i>Exp Hematol</i> . 2000 May;28(5):558-68. | |
| | C63 | DELGADO, Textbook of Organic Medicinal and Pharmaceutical Chemistry, Ninth Edition, Remers, ed., 1991:30-1. | |
| | C64 | DENZEL <i>et al.</i> Imidazo [4,5-c]- and [4,5-b]pyridines. <i>J. Heterocyclic Chem.</i> 1977;14:813-821. | |
| | C65 | DI CARLO <i>et al.</i> , Neutrophils in anti-cancer immunological strategies: old players in new games. <i>J Hematother Stem Cell Res</i> . 2001 Dec;10(6):739-48. | |
| | C66 | DIAZ-ARRASTIA <i>et al.</i> , Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. <i>Clin Cancer Res</i> . 2001 Oct;7(10):3031-3. | |
| | C67 | DICKEN <i>et al.</i> , Reactions at High Pressures. [3 + 2] Dipolar Cycloaddition of Nitrones with Vinyl Ethers. <i>J Org Chem</i> . 1982;47:2047-51. | |
| | C68 | DOCKRELL <i>et al.</i> , Imiquimod and resiquimod as novel immunomodulators. <i>J Antimicrob Chemother</i> . 2001 Dec;48(6):751-5. | |
| | C69 | DOUGLAS, Introduction to Viral Diseases. In: Cecil Textbook of Medicine. Bennet <i>et al.</i> , eds. 20th Ed. W.B. Saunders Company. 1996:2:1739-47. | |
| | C70 | DOYLE <i>et al.</i> , Toll-like receptor 3 mediates a more potent antiviral response than Toll-like receptor 4. <i>J Immunol</i> . 2003 Apr 1;170(7):3565-71. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 35 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C71 | DREXLER <i>et al.</i> , Bryostatin 1 induces differentiation of B-chronic lymphocytic leukemia cells. Blood. 1989 Oct;74(5):1747-57. | |
| | C72 | DZIOBEK <i>et al.</i> BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol. 2000 Dec 1;165(11):6037-46. | |
| | C73 | EDWARDS <i>et al.</i> , Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol. 2003 Apr;33(4):827-33. | |
| | C74 | ERIKS <i>et al.</i> , Histamine H2-receptor agonists. Synthesis, in vitro pharmacology, and qualitative structure-activity relationships of substituted 4- and 5-(2-aminoethyl)thiazoles. J Med Chem. 1992 Aug 21;35(17):3239-46. | |
| | C75 | FECCI <i>et al.</i> , The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. J Neurooncol. 2003 Aug-Sep;64(1-2):161-76. | |
| | C76 | FITZGERALD-BOCARSLY <i>et al.</i> , Virally-Responsive IFN- α Producing Cells in Human Blood and Tonsil Are CD11C/CD123+ Cells Identical to Precursors of Type Two Dendritic Cells (pDC2). J Interferon Cytokine Res. 1999;19(1):S117. | |
| | C77 | FLO <i>et al.</i> , Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem. 2002 Sep 20;277(38):35489-95. Epub 2002 Jun 27. | |
| | C78 | FONTENAU <i>et al.</i> , Human Immunodeficiency Virus Type 1 Activates Plasmacytoid Dendritic Cells and Concomitantly Induces the Bystander Maturation of Myeloid Dendritic Cells. J Virol. 2003;78(10):5223-32. | |
| | C79 | FRANKEL <i>et al.</i> , The Preparation of N-Disubstituted Formamides. Tetrahedron Lett. 1959;7:5-7. | |
| | C80 | FRANTZ <i>et al.</i> , Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest. 1999 Aug;104(3):271-80. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 36 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C81 | FU <i>et al.</i> , Regioselective Catalytic Hydrogenation of Polycyclic Aromatic Hydrocarbons under Mild conditions. J Org Chem. 1980;45:2979-803. | |
| | C82 | FUCHSBERGER <i>et al.</i> , Priming Interferon-a 1 or Interferon-a 2 Enhances the Production of Both Subtypes Simultaneously. J Interferon and Cytokine Res. 1995;15:637-39. | |
| | C83 | GALOSE, DAPSONE (diaminodiphenylsulphone DDS). Clinical Toxicology Review. 1999;21(9). 3 pages. | |
| | C84 | GENDRON, Loxosceles ecluse envenomation. Am J Emerg Med. 1990 Jan;8(1):51-4. | |
| | C85 | GENEVOIS-BORELLA <i>et al.</i> , Synthesis of 1-(3-R-Amino-4-Hydroxy Butyl)thymine Acyclonucleoside. Analogs as Potential Anti-AIDS Drugs. Tetrahedron Lett. 1990;31:4879-82. | |
| | C86 | GIBSON <i>et al.</i> , Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res. 1995 Jun;15(6):537-45. | |
| | C87 | GIBSON <i>et al.</i> , Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002 Jul-Aug;218(1-2):74-86. | |
| | C88 | GITELSON <i>et al.</i> , Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res. 2003 May;9(5):1656-65. | |
| | C89 | GOMEZ <i>et al.</i> , Intradermal anti-loxosceles Fab fragments attenuate demonecrotic arachnidism. Acad Emerg Med. 1999;6:1195-202. | |
| | C90 | GORDEN <i>et al.</i> , Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J Immunol. 2005 Feb 1;174(3):1259-68. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 37 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C91 | GORDON, Pattern recognition receptors: doubling up for the innate immune response. Cell. 2002 Dec 27;111(7):927-30. | |
| | C92 | GÜRSEL <i>et al.</i> , Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol. 2002 May;71(5):813-20. | |
| | C93 | GUNNING <i>et al.</i> , Chemoprevention by lipoxygenase and leukotriene pathway inhibitors of vinyl carbamate-induced lung tumors in mice. Cancer Res. 2002 Aug 1;62(15):4199-201. | |
| | C94 | HART, Napthyridines Hydroxynaphthyridines, Journal of Chemical Society, 1956;Part III:212-4. | |
| | C95 | HARTMANN <i>et al.</i> , Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur J Immunol. 2003 Jun;33(6):1633-41. | |
| | C96 | HAYASHI Toll-like receptors stimulate human neutrophil function. Blood. 2003 Oct 1;102(7):2660-9. Epub 2003 Jun 26. | |
| | C97 | HAYES <i>et al.</i> , Regulation of Interferon Production by Human Monocytes: Requirements for Priming for Lipopolysaccharide-Induced Production. J Leukocyte Biol. 1991;50:176-81. | |
| | C98 | HEIL <i>et al.</i> , Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004 Mar 5;303(5663):1526-9. Epub 2004 Feb 19. | |
| | C99 | HEIL <i>et al.</i> , Synthetic immunostimulatory compounds activate immune cells via TLR7 and TLR8. 33th Annual Meeting of the Deutsche Gessellschaft Mr Immunologie, Marburg 2002. Abstract C.6. | |
| | C100 | HEMMI <i>et al.</i> , Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002 Feb;3(2):196-200. Epub 2002 Jan 22. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Nillofar Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 38 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C101 | HOBBS <i>et al.</i> , Comparison of hyperbaric oxygen and dapsone therapy for loxosceles envenomation. Acad Emerg Med. 1996 Aug;3(8):758-61. | |
| | C102 | HOFFMAN <i>et al.</i> , Conformational requirements for histamine H2-receptor inhibitors: a structure-activity study of phenylene analogues related to cimetidine and tiotidine. J Med Chem. 1983 Feb;26(2):140-4. | |
| | C103 | HOFMANOVÁ <i>et al.</i> , Lipoygenase inhibitors induce arrest of tumor cells in S-phase of the cell cycle. Neoplasma. 2002;49(6):362-7. | |
| | C104 | HOLLADAY <i>et al.</i> , Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. Bioorg Med Chem Lett. 1998 Oct 6;8(19):2797-802. | |
| | C105 | HORNG <i>et al.</i> , The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature. 2002 Nov 21;420(6913):329-33. | |
| | C106 | HORNUNG <i>et al.</i> , Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. Journal of Immunol. 2002;168:4531-37. | |
| | C107 | HOUBEN-WEYL, Quinoline and Isoquinoline. Methoden der Organischen Chemie. 1980:271-79. German. | ✓ |
| | C108 | HOUSTON <i>et al.</i> , Potential inhibitors of S-adenosylmethionine-dependent methyltransferases. 8. Molecular dissections of carbocyclic 3-deazaadenosine as inhibitors of S-adenosylhomocysteine hydrolase. J Med Chem. 1985 Apr;28(4):467-71. | |
| | C109 | HUPPATZ, Systemic fungicides. The synthesis of certain pyrazole analogues of carboxin. Aust J Chem. 1983;36:135-47. | |
| | C110 | IINO <i>et al.</i> , Treatment of Chronic Hepatitis C With High-Dose Interferon α-2b. Multicenter Study. Dig Dis Sci. 1993;38(4):612-18. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 39 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C111 | ITO <i>et al.</i> , Interferon- α and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med. 2002 Jun 3;195(11):1507-12. | |
| | C112 | IWASHITA <i>et al.</i> , Syntheses of Isoretronecanol and Lupinine. J Org Chem. 1982;47:230-33. | |
| | C113 | JACOBS, The Synthesis of Acetylenes. In: Organic Reactions. New York: Wiley & Sons, Inc., 1949. Volume 5. 1-78. | |
| | C114 | JAHNSEN <i>et al.</i> , Extensive recruitment of IL-3R α high dendritic-cell precursors to allergic nasal mucosa during allergen challenge. Immunology Lett. 1999;69(1):123. Abstract #32.2. | |
| | C115 | JURK <i>et al.</i> Human TLR7 and TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol. 2002 Jun;3(6):499. | |
| | C116 | JUWEID, Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice. J Nuclear Med. 2002;43(11):1507-29. | |
| | C117 | KATRITSKY <i>et al.</i> , Comprehensive Heterocyclic Chemistry: The Structure, Reactions, Synthesis and Uses of Heterocyclic Compounds. 1984;2:586-587. | |
| | C118 | KEATING <i>et al.</i> , Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood. 1993 Jun 1;81(11):2878-84. | |
| | C119 | KLAUSEN <i>et al.</i> , Two complementary methods of assessing periodontal bone level in rats. Scand J Dent Res. 1989 Dec;97(6):494-9. | |
| | C120 | KLINMAN, Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol. 2004 Apr;4(4):249-58. | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | | |
|---|------------|----|----|--------------------------|------------------------|--|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | | |
| | | | | Application Number | 10/595,103-Conf. #2609 | |
| | | | | Filing Date | February 14, 2006 | |
| | | | | First Named Inventor | Kyle J. Lindstrom | |
| | | | | Art Unit | 1625 | |
| Examiner Name | N. Rahmani | | | | | |
| Sheet | 40 | of | 57 | Attorney Docket Number | C1271.70021US02 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C121 | KLOEK <i>et al.</i> , An Improved Method for the Synthesis of Stabilized Primary Enamines and Imines. J Org Chem. 1978;43:1460-62. | |
| | C122 | KLOETZEL, Reactions of nitroparaffins. I. Synthesis and reduction of some o-nitrokenes. J Am Chem Soc. 1947;69:2271-2275. | |
| | C123 | KORNMAN, Host modulation as a therapeutic strategy in the treatment of periodontal disease. Clin Infect Dis. 1999 Mar;28(3):520-6. | |
| | C124 | KOURAFALOS <i>et al.</i> , Synthesis of 7-aminopyrazolo[3,4-c]pyridine as a probe for the preparation of compounds of pharmacological interest. Heterocycles. 2002;57(12):2335-2343. | |
| | C125 | KRAUSE <i>et al.</i> , Autoimmune aspects of cytokine and anticytokine therapies. Am J Med. 2003 Oct 1;115(5):390-7. | |
| | C126 | KRENITSKY <i>et al.</i> , Imidazo[4,5-c]pyridines (3-deazapurines) and their nucleosides as immunosuppressive and anti-inflammatory agents. J Med Chem. 1986 Jan;29(1):138-43. | |
| | C127 | KURT-JONES <i>et al.</i> , Role of toll-like receptor 2 (TLR2) in neutrophil activation: GM-CSF enhances TLR2 expression and TLR2-mediated interleukin 8 responses in neutrophils. Blood. 2002 Sep 1;100(5):1860-8. | |
| | C128 | LALL <i>et al.</i> , Serine and threonine beta-lactones: a new class of hepatitis A virus 3C cysteine proteinase inhibitors. J Org Chem. 2002 Mar 8;67(5):1536-47. | |
| | C129 | LEE <i>et al.</i> , p38 mitogen-activated protein kinase inhibitors – mechanisms and therapeutic potentials. Pharmacol Ther. 1999;82:389-97. | |
| | C130 | LEE <i>et al.</i> , Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem. 2004 Apr 23;279(17):16971-9. Epub 2004 Feb 13. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofar Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|--|----|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete if Known | | |
| | | | Application Number | 10/595,103-Conf. #2609 | |
| | | | Filing Date | February 14, 2006 | |
| | | | First Named Inventor | Kyle J. Lindstrom | |
| | | | Art Unit | 1625 | |
| | | | Examiner Name | N. Rahmani | |
| Sheet | 41 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C131 | LEHNER <i>et al.</i> , The role of $\gamma\delta$ cells and β -chemokines in mucosal protection against SIV infection. <i>Immunology Lett.</i> 1999;69:25-192. Abstract 2.1 | |
| | C132 | LEVY <i>et al.</i> , Unique efficacy of Toll-like receptor 8 agonists in activating human neonatal antigen-presenting cells. <i>Blood</i> . 2006 Aug 15;108(4):1284-90. Epub 2006 Apr 25. | |
| | C133 | LEYNADIER <i>et al.</i> , Allergic reactions to North African scorpion venom evaluated by skin test and specific IgE. <i>J Allergy Clin Immunol.</i> 1997 Jun;99(6 Pt 1):851-3. 4 pages. | |
| | C134 | LI <i>et al.</i> , An improved protocol for the preparation of 3-pyridyl- and some arylboronic acids. <i>J Org Chem.</i> 2002 Jul 26;67(15):5394-7. | |
| | C135 | LI <i>et al.</i> , Solubility behavior of imiquimod in alkanolic acids. <i>Pharmaceutical Research</i> . 1997 American Association of Pharmaceutical Scientists Annual Meeting. Poster Presentation, Boston, MA, Nov. 2-6, 1997;S475:Abstract 3029. | |
| | C136 | LI <i>et al.</i> , Synthesis, CoMFA analysis, and receptor docking of 3,5-diacetyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists. <i>J Med Chem.</i> 1999 Feb 25;42(4):706-21. | |
| | C137 | LITT <i>et al.</i> , Mucosal delivery of vaccine antigens displayed on the surface of <i>Lactococcus lactis</i> . <i>Immunology Lett.</i> 1999;69(1):61. Abstract #11.26. | |
| | C138 | LIU <i>et al.</i> , Synthesis of halogen-substituted 3-deazaadenosine and 3-deazaguanosine analogues as potential antitumor/antiviral agents. <i>Nucleosides Nucleotides Nucleic Acids</i> . 2001 Dec;20(12):1975-2000. | |
| | C139 | LOESCHE <i>et al.</i> , Treatment paradigms in periodontal disease. <i>Compend Contin Educ Dent.</i> 1997 Mar;18(3):221-6, 228-30, 232 passim; quiz 234. Review. | |
| | C140 | LUGER <i>et al.</i> , Evidence for an epidermal cytokine network. <i>J Invest Dermatol.</i> 1990 Dec;95(6 Suppl):100S-104S. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 42 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C141 | LUSKIN <i>et al.</i> , Olefinic Derivatives of 2,4-Diamino-s-triazines. J Org Chem. 1958;23:1032-37. | |
| | C142 | MACCHIA <i>et al.</i> , Synthesis and antiviral properties of 9-[(2-methyleneaminoxymethoxy)methyl]guanine derivatives as novel Acyclovir analogues. Farmaco. 2000 Feb;55(2):104-8. | |
| | C143 | MAJESKI <i>et al.</i> , Action of venom from the brown recluse spider (<i>Loxosceles ecluse</i>) on human neutrophils. Toxicol. 1977;15(5):423-7. | |
| | C144 | MAKARENKOVA <i>et al.</i> , Identification of delta- and mu- type opioid receptors on human and murine dendritic cells. J Neuroimmunol. 2001;117:68-77. | |
| | C145 | MASIH, Progress on novel immunomodulatory agents for HIV-1 infection and other infectious diseases. Expert Opin Ther Patents. 2003;13(6):867-82. | |
| | C146 | MASIUKIEWICZ <i>et al.</i> , Scalable Syntheses of N ^α -Benzyloxycarbonyl-L-Ornithine and of N ^α -(9-Fluorenylmethoxy)Carbonyl-L-Ornithine. Org Prep Proced Int. 2002;34:531-37. | |
| | C147 | MATAKA <i>et al.</i> , Condensation reaction of 3,4-Dibenzoyl-1-methyl-2,5-diphenylpyrrole and -1-phenylpyrazole with methylamine derivatives affording pyrrolo [3,4-c] pyridine and 2H-pyrazolo[3,4-c]- and [4,3-c]pyridines. Journal of Heterocyclic Chemistry. 1981;18(6):1073-5. | |
| | C148 | MATHUR <i>et al.</i> , Cell-mediated immune system regulation in periodontal diseases. Crit Rev Oral Biol Med. 1997;8(1):76-89. | |
| | C149 | MAYNOR <i>et al.</i> , Brown recluse spider envenomation: a prospective trial of hyperbaric oxygen therapy. Acad Emerg Med. 1997 Mar;4(3):184-92. | |
| | C150 | MBOW <i>et al.</i> , Small molecule and biologic modulators of the immune response to hepatitis C virus. Mini Rev Med Chem. 2006 May;6(5):527-31. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 43 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C151 | MCCARTHY <i>et al.</i> , Opioids, opioid receptors, and the immune response. Drug & Alcohol Dependence. 2001;62:111-23. | |
| | C152 | MCKENNON <i>et al.</i> , A Convenient Reduction of Amino Acids and Their Derivatives. J Org Chem. 1993;58:3568-71. | |
| | C153 | MCLAUGHLIN <i>et al.</i> , Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice. Cancer Lett. 2003;199:209-17. | |
| | C154 | MEDZHITOV, Toll-Like Receptors and Innate Immunity. Nature Rev Immunol. 2001;1:135-45. | |
| | C155 | MEE <i>et al.</i> , Stille coupling made easier - the synergic effect of copper(I) salts and the fluoride ion. Angew Chem. 2004;116:1152-56. | |
| | C156 | MERIGIAN <i>et al.</i> , Envenomation From the Brown Recluse Spider: Review of Mechanism and Treatment Options. Am J Ther. 1996 Oct;3(10):724-734. | |
| | C157 | MILLER <i>et al.</i> , Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999 Jan;21(1):1-14. | |
| | C158 | MINAKAWA <i>et al.</i> , Nucleosides and Nucleotides. 184. Synthesis and Conformational Investigation of Anti-Fixed 3-Deaza-3-halopurine Ribonucleosides. J Org Chem. 1999;64:7158-72. | |
| | C159 | MOEBIUS <i>et al.</i> , The mysteries of sigma receptors: new family members reveal a role in cholesterol synthesis. Trends Pharmacol Sci. 1997 Mar;18(3):67-70. | |
| | C160 | MOLDOVEANU <i>et al.</i> , Poly-L-lysine as a potential mucosal adjuvant. Immunology Lett. 1999;69(1):62. Abstract #11.28. | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Nilofar Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 44 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C161 | MOLLIK <i>et al.</i> , MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. <i>Cancer Immun.</i> 2003 Mar 17;3:3. 17 pages. | |
| | C162 | MOODY <i>et al.</i> , Lipoxigenase inhibitors prevent lung carcinogenesis and inhibit non-small cell lung cancer growth. <i>Exp Lung Res.</i> 1998 Jul-Aug;24(4):617-28. | |
| | C163 | MORACZEWSKI <i>et al.</i> , Using Hydrogen Bonding to Control Carbamate C-N Rotamer Equilibria. <i>Org Chem.</i> 1998 Oct 16;63(21):7258-7262. | |
| | C164 | MOSBECH <i>et al.</i> , [Allergy to insect stings] <i>Ugeskr Laeger.</i> 1991 Oct 28;153(44):3067-71. Danish. | ✓ |
| | C165 | MUCHE <i>et al.</i> , Imiquimod treatment of cutaneous T cell lymphoma. <i>Journal of Investigative Dermatology.</i> 2003 July;121(1):0975. Joint Meeting of the European Society for Dermatology; Miami Beach, Florida, USA. April 30-May 04, 2003. Abstract 0975. | |
| | C166 | MULLER <i>et al.</i> , An improved one-pot procedure for the synthesis of alkynes from aldehydes. <i>Synlett.</i> 1996;6:521-522. | |
| | C167 | MUTSCHLER <i>et al.</i> , 9.2 Anti-infectives. In: <i>Drug Actions: Basic Principles and Therapeutic Aspects.</i> 1995:515-23. | |
| | C168 | MUZIO <i>et al.</i> , Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. <i>J Immunol.</i> 2000 Jun 1;164(11):5998-6004. | |
| | C169 | NAGARAJAN <i>et al.</i> , Condensed heterotricycles: synthesis of pyrazolo[3,4-c]quinoline derivatives. <i>Indian Journal of Chemistry.</i> 1992;31B:316-321. | |
| | C170 | NAGASE <i>et al.</i> , Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. <i>J Immunol.</i> 2003 Oct 15;171(8):3977-82. | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Nilofar Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 45 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C171 | NANJAPPAN <i>et al.</i> , An efficient synthesis of some 6-substituted 4,8-diaza-3,3,9,9-tetramethylundeca-2,10-dione dioximes (propylene amine oximes, PnAOs): Ligands for 99mTc complexes used in structure distribution relationship (SDR) studies. Tetrahedron. 1994;50(29):8617-32. | |
| | C172 | OHANA <i>et al.</i> , Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. Journal of Cellular Physiology. 2001 Jan;186(1):19-23. Review. | |
| | C173 | O'MAHONY <i>et al.</i> , New patient-applied therapy for anogenital warts is rated favourably by patients. Int J STD & AIDS. 2001;12:565-70. | |
| | C174 | OSOL <i>et al.</i> , Chapter 27: Structure-Activity Relationship and Drug Design. In: Remington's Pharmaceutical Sciences. 16th Ed. Mach Publishing. 1980:420-35. | |
| | C175 | OTTONELLO <i>et al.</i> , Sulphonamides as anti-inflammatory agents: old drugs for new therapeutic strategies in neutrophilic inflammation? Clin Sci (Lond). 1995 Mar;88(3):331-6. | |
| | C176 | OZINSKY <i>et al.</i> , The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc. Nat. Acad. Sci. 2000; 97(25):13766-71. | |
| | C177 | PAGE <i>et al.</i> , Advances in the pathogenesis of periodontitis: summary of developments, clinical implications and future directions. Periodontol 2000. 1997 Jun;14:216-48. | |
| | C178 | PARK <i>et al.</i> , Immunotherapy Cancer Treatment. Reprinted from Supportive Cancer Care, Rosenbaum <i>et al.</i> 2001. Available at http://www.cancersupportivecare.com/immunotherapy.html . Last accessed July 13, 2010. 3 pages. | |
| | C179 | PARK <i>et al.</i> , Sodium Dithionite Reduction of Nitroarenes Using Viologen as an Electron Phase-Transfer Catalyst. Tetrahedron Lett. 1993;34(46):7445-46. | |
| | C180 | PATEL <i>et al.</i> , The necrotic venom of the brown recluse spider induces dysregulated endothelial cell-dependent neutrophil activation. Differential induction of GM-CSF, IL-8, and E-selectin expression. J Clin Invest. 1994 Aug;94(2):631-42. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 46 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|--|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C181 | PATRICK <i>et al.</i> , Paragraph 10.3: Drug optimization: strategies in drug design. In: An Introduction to Medicinal Chemistry. Oxford: Oxford University Press. January 2005. 200-218. | |
| | C182 | PAVLETIC <i>et al.</i> , Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant. 2000 Apr;25(7):717-22. | |
| | C183 | PAWLAS <i>et al.</i> , Novel anionic annelation tactics for construction of fused heteroaromatic frameworks. 1. Synthesis of 4-substituted pyrazolo[3,4-c]quinolines, 9-substituted pyrazolo[3,4-c]quinolines, and 1,4-dihydrochromeno[4,3-c]pyrazoles. Org Chem. 2001 Jun 15;66(12):4214-9. | |
| | C184 | PAYVANDI <i>et al.</i> , Exogenous and Endogenous IL-10 Regulate IFN- α Production by Peripheral Blood Mononuclear Cells in Response to Viral Stimulation. J Immunol. 1998;160:5861-68. | |
| | C185 | PESCHKE <i>et al.</i> , Synthesis and in vitro characterization of new growth hormone secretagogues derived from ipamorelin with dipeptidomimetic N-terminals. Eur J Med Chem. 1999;34:363-380. | |
| | C186 | PETERSON <i>et al.</i> , The opioid-cytokine connection. J Neuroimmunol. 1998;83:63-69. | |
| | C187 | PHILLIPS <i>et al.</i> , Therapy of brown spider envenomation: a controlled trial of hyperbaric oxygen, dapsone, and cyproheptadine. Ann Emerg Med. 1995 Mar;25(3):363-8. | |
| | C188 | PICKERSGILL <i>et al.</i> , Preparation of functionalized, conformationally constrained DTPA analogues from L- or D-serine and trans-4-hydroxy-L-proline. Hydroxymethyl substituents on the central acetic acid and on the backbone. J Org Chem. 2000 Jun 30;65(13):4048-57. | |
| | C189 | POLJAKOVIC <i>et al.</i> , iNOS and COX-2 immunoreactivity in the mice bladder and kidney after bacterial instillation. Immunology Lett. 1999;69(1):122. Abstract #31.5. | |
| | C190 | POWELL <i>et al.</i> , Compendium of excipients for parenteral formulations. PDA J Pharm Sci Technol. 1998 Sep-Oct;52(5):238-311. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 47 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C191 | PRELOG <i>et al.</i> , Cycloalkeno-pyridine. <i>Helv Chem Acta</i> . 1945;28:1684-93. German. | |
| | C192 | REES <i>et al.</i> , Brown recluse spider bites. A comparison of early surgical excision versus dapsone and delayed surgical excision. <i>Ann Surg</i> . 1985 Nov;202(5):659-63. | |
| | C193 | REGAN <i>et al.</i> , Activation of p38 MAPK by feline infectious peritonitis virus regulates pro-inflammatory cytokine production in primary blood-derived feline mononuclear cells. <i>Virology</i> . 2009 Feb 5;384(1):135-43. Epub 2008 Dec 5. | |
| | C194 | RHODES, Discovery of immunopotentiatory drugs: current and future strategies. <i>Clin Exp Immunol</i> . 2002 Dec;130(3):363-9. | |
| | C195 | RIBERA <i>et al.</i> , "Spontaneous" complete remissions in chronic lymphocytic leukemia: report of three cases and review of the literature. <i>Blood Cells</i> . 1987;12(2):471-83. | |
| | C196 | RITTER <i>et al.</i> , A new reaction of nitriles; amides from alkenes and mononitriles. <i>J Am Chem Soc</i> . 1948 Dec;70(12):4045-8. | |
| | C197 | ROCCA <i>et al.</i> , Carbolines. Part VII. Ansindines, Convenient tools to synthesize efficient-β-carbolines. <i>J Heterocyclic Chem</i> . 1995;32:1171-1175. | |
| | C198 | ROCCA <i>et al.</i> , Connection between metalation and cross-coupling strategies. A new convergent route to azacarbazoles. 1993;49(1):49-64. | |
| | C199 | ROLLINS <i>et al.</i> , Chemokines. <i>Blood</i> . 1997 Aug 1;90(3):909-28. Review. | |
| | C200 | ROSENBERG <i>et al.</i> , Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. <i>JAMA</i> . 1994 Mar 23-30;271(12):907-13. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 48 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C201 | ROTHEL <i>et al.</i> , The use of recombinant ovine IL-1beta and TNF-alpha as natural adjuvants and their physiological effects in vivo. Immunol Cell Biol. 1998 Apr;76(2):167-72. | |
| | C202 | ROY <i>et al.</i> , QSAR of adenosine receptor antagonists II: exploring physicochemical requirements for selective binding of 2-arylpyrazolo[3,4-c] quinoline derivatives with adenosine A1 and A3 receptor subtypes. QSAR & Comb Sci. 2003;22:614-621. | |
| | C203 | ROYALS <i>et al.</i> , Studies in mixed ester condensations. IV. Acylations with methyl dimethoxyacetate. J Am Chem Soc. 1956;78:4161-4164. | |
| | C204 | ROZMAN <i>et al.</i> , Chronic lymphocytic leukemia. N Engl J Med. 1995 Oct 19;333(16):1052-7. | |
| | C205 | SAKTHIVEL <i>et al.</i> Direct SnAr amination of fluorinated imizazo[4,5-c]pyridine nucleosides: efficient synthesis of 3-fluoro-3-3-deazaadenosine analogs. Tetrahedron Letters. 2005 May;46(22):3883-3887. | |
| | C206 | SALAUN <i>et al.</i> , TLR3 Can Directly Trigger Apoptosis in Human Cancer Cells. J of Immunology. 2006;176:4894-901. | |
| | C207 | SALEMINK, Uber 2-Propyl-1- Und 2-Propyl-Desaza-Adenin. Recueil. 1961;80:545-56. German. | |
| | C208 | SAMBHI <i>et al.</i> , Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci U S A. 1991 May 1;88(9):4025-9. | |
| | C209 | SAMS <i>et al.</i> , Necrotic arachnidism. J Am Acad Dermatol. 2001 Apr;44(4):561-73; quiz 573-6. | |
| | C210 | SAUDER <i>et al.</i> , Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults. Antimicrobial Agents Chemo. 2003;47(12):3846-52. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 49 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C211 | SCHEERLINCK, Genetic adjuvants for DNA vaccines. Vaccine. 2001 Mar 21;19(17-19):2647-56. | |
| | C212 | SCHEUER <i>et al.</i> , Application of the Ritter reaction to mesityl oxide and chalcone. J Am Chem Soc. 1957;22:674-676. | |
| | C213 | SCHOFIELD <i>et al.</i> , Reply. Low-Dose Interferon-alpha in Chronic Myeloid Leukemia. Ann Internal Med. 1995;122(9):728-29. 1 page. | |
| | C214 | SCHWANDNER <i>et al.</i> , Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999 Jun 18;274(25):17406-9. | |
| | C215 | SEEMAN <i>et al.</i> , Steric and Conformational Effects in Nicotine Chemistry. J Org Chem. 1981;46:3040-48. | |
| | C216 | SERRAT <i>et al.</i> , A highly efficient and straightforward stereoselective synthesis of novel chiral α -acetylenic ketones. Tetrahedron: Asymmetry. 1999;10:3417-30. | |
| | C217 | SEVERA <i>et al.</i> , Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells. J Immunol. 2007 May 15;178(10):6208-16. | |
| | C218 | SEYMOUR <i>et al.</i> , Cellular immunity and hypersensitivity as components of periodontal destruction. Oral Dis. 1996 Mar;2(1):96-101. Review. | |
| | C219 | SHELBOURNE <i>et al.</i> , Quantitation of Bacteroids forsythus in subgingival plaque comparison on immunoassay and quantitative polymerase chain reaction. J Microbiol Methods. 2000;39:97-107. | |
| | C220 | SIDKY <i>et al.</i> , Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res. 1992 Jul 1;52(13):3528-33. | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 50 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C221 | SIEGAL <i>et al.</i> , The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999 Jun 11;284(5421):1835-7. | |
| | C222 | SLETZINGER <i>et al.</i> , The Synthesis of Isomethadone. J Am Chem Soc. 1952;74:5619-20. | |
| | C223 | SMITH <i>et al.</i> , The role of polymorphonuclear leukocytes in the lesion caused by the venom of the brown spider, <i>Loxosceles ecluse</i> . Lab Invest. 1970 Jan;22(1):90-3. | |
| | C224 | SOFINA <i>et al.</i> , Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations. NCI Monograph 55. NIH Publication No. 80-1933. 1980:76-8. | |
| | C225 | SONOGASHIRA <i>et al.</i> , A convenient synthesis of acetylenes: catalytic substitutions of acetylenic hydrogen with bromoalkenes, Iodoarenes, and bromopyridines. Tetrahedron Letts. 1975;50:4467-4470. | |
| | C226 | SORIA <i>et al.</i> , Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther. 2000 Oct;38(10):476-81. | |
| | C227 | SPANER <i>et al.</i> , A phase I/II trial of TLR -7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia. 2010; 24:222-26. | |
| | C228 | SPANER <i>et al.</i> , Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia. 2006 Feb;20(2):286-95. | |
| | C229 | SPANER <i>et al.</i> , Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia. 2007 Jan;21(1):53-60. Epub 2006 Oct 26. | |
| | C230 | SPIVEY <i>et al.</i> , Configurationally stable biaryl analogues of 4-(dimethylamino)pyridine: A novel class of chiral nucleophilic catalysts. J Org Chem. 1999;64:9430-9443. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 51 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C231 | SPRUANCE <i>et al.</i> , Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis. 2001 Jul 15;184(2):196-200. Epub 2001 Jun 8. | |
| | C232 | STACK, Images in clinical medicine. Latrodectus mactans. N Engl J Med. 1997 Jun 5;336(23):1649. | |
| | C233 | STANLEY, Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol. 2002 Oct;27(7):571-7. Review. | |
| | C234 | STASHENKO <i>et al.</i> , Periapical inflammatory responses and their modulation. Crit Rev Oral Biol Med. 1998;9(4):498-521. | |
| | C235 | STEELE <i>et al.</i> , Lipoxigenase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev. 1999 May;8(5):467-83. | |
| | C236 | STEELE <i>et al.</i> , Potential use of lipoxigenase inhibitors for cancer chemoprevention. Expert Opin Investig Drugs. 2000 Sep;9(9):2121-38. | |
| | C237 | STEINMANN <i>et al.</i> , Topical imiquimod treatment of a cutaneous melanoma metastasis. J Am Acad Dermatol. 2000 Sep;43(3):555-6. | |
| | C238 | STEWART <i>et al.</i> , Synthesis of a Carba-analog of S-Acetyl Coenzyme A, Acetyl-dethio Coenzyme A; an Effective Inhibitor of Citrate Synthase. Liebigs Ann Chem. 1978:57-65. | |
| | C239 | STILLINGS <i>et al.</i> , Substituted 1,3,4-thiadiazoles with anticonvulsant activity. 2. Aminoalkyl derivatives. J Med Chem. 1986 Nov;29(11):2280-4. | |
| | C240 | STRANDTMANN <i>et al.</i> , Reaction of cyclic β -diketones with 3,4-dihydroisoquinolines and related compounds. Preparation and anticancer activity of 2-substituted 1,3-cyclohexanediones. J Med Chem. 1967 Nov;10(6):1063-5. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|----|----|--------------------------|------------------------|-----------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Complete If Known | | |
| | | | Application Number | 10/595,103-Conf. #2609 | |
| | | | Filing Date | February 14, 2006 | |
| | | | First Named Inventor | Kyle J. Lindstrom | |
| | | | Art Unit | 1625 | |
| | | | Examiner Name | N. Rahmani | |
| Sheet | 52 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C241 | STRINGFELLOW, Induction of interferon with low molecular weight compounds: fluorenone esters, ethers (tilorone), and pyrimidinones. <i>Methods Enzymol.</i> 1981;78(Pt A):262-84. | |
| | C242 | STRÖHER <i>et al.</i> , Progress towards the treatment of Ebola haemorrhagic fever. <i>Expert Opin Investig Drugs.</i> 2006 Dec;15(12):1523-35. | |
| | C243 | SUGISAKA <i>et al.</i> , The Physicochemical properties of imiquimod, the first imidazoquinoline immune response modifier. <i>Pharmaceutical Research.</i> 1997 American Association of Pharmaceutical Scientists Annual Meeting. Poster Presentation, Boston, MA, Nov. 2-6, 1997;S475:Abstract 3030. | |
| | C244 | SURREY <i>et al.</i> , The Synthesis of Some 3-Nitro- and 3-Amino-4-dialkylaminoalkylaminoquinoline Derivatives. <i>J Am Chem Soc.</i> 1951;73:2413-16. | |
| | C245 | TAKEICHI <i>et al.</i> , Cytokine profiles of T-lymphocytes from gingival tissues with pathological pocketing. <i>J Dent Res.</i> 2000 Aug;79(8):1548-55. | |
| | C246 | TAKESHITA <i>et al.</i> , Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. <i>Semin Immunol.</i> 2004 Feb;16(1):17-22. | |
| | C247 | TAKEUCHI <i>et al.</i> , Discrimination of bacterial lipoproteins by Toll-like receptor 6. <i>Int Immunol.</i> 2001 Jul;13(7):933-40. | |
| | C248 | TEMPLE <i>et al.</i> , Potential anticancer agents: 5-(N-substituted-aminocarbonyl)- and 5-(N-substituted-aminothiocarbonyl)-5,6,7,8-tetrahydrofolic acids. <i>J Med Chem.</i> 1988 Mar;31(3):697-700. | |
| | C249 | THESING <i>et al.</i> , [Darstellung und Eigenschaften des Δ^1 -Pyrrolin-N-oxys.]. <i>Chem Ber.</i> 1959;92:1748-55. German. | |
| | C250 | THIRUVIKRAMAN <i>et al.</i> , Synthesis and reactions of pyrazolo-[3,4-c]quinoline derivatives. <i>Indian Journal of Chemistry.</i> 1987;26B:695-696. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 53 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C251 | TOMAI <i>et al.</i> , Imiquimod: in vivo and in vitro characteristics and toxicology. In: Cutaneous Infection and Therapy. Aly <i>et al.</i> , eds. Marcel Dekkar, Inc., New York. 1997:406-15. | |
| | C252 | TOMIC <i>et al.</i> , Sensitization of IL-2 Signaling through TLR-7 Enhances B Lymphoma Cell Immunogenicity. J Immunol. 2006;176:3830-39. | |
| | C253 | TOMIOKA <i>et al.</i> , Asymmetric Alkylation of α -Alkyl β -Keto Esters. J Am Chem Soc. 1984;106:2718-19. | |
| | C254 | TOTTERMAN <i>et al.</i> , Phorbol ester-induced differentiation of chronic lymphocytic leukaemia cells. Nature. 1980 Nov 13;288(5787):176-8. | |
| | C255 | TRACY <i>et al.</i> , Studies in the Pyridine Series. II. Synthesis of 2-Methyl-3-(β -Hydroxyethyl)pyridine and of the Pyridine Analog of Thiamine (Vitamin B2). J Org Chem. 1941;6:54-62. | |
| | C256 | UNO <i>et al.</i> , TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells. Blood. 2003 May 1;101(9):3658-67. Epub 2002 Dec 27. | |
| | C257 | UROSEVIC <i>et al.</i> , Imiquimod treatment induces expression of opioid growth factor receptor: a novel tumor antigen induced by interferon-alpha? Clin Cancer Res. 2004 Aug 1;10(15):4959-70. | |
| | C258 | VAN DE KERHOF, New Immunomodulatory Drugs. In: Skin and Environment: Perception and Protection. Ring <i>et al.</i> , eds., 10th EADV Congress, October 10-14, Munich, Germany. 2001:1:343-38. | |
| | C259 | VASILAKOS <i>et al.</i> , Adjuvant Activities of Immune Response Modifier R-848: Comparison with CoG ODN. Cell Immunol. 2000;204:64-74. | |
| | C260 | VIEWEG <i>et al.</i> , Tumor vaccines: from gene therapy to dendritic cells-the emerging frontier. Urol Clin North Am. 2003 Aug;30(3):633-43. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete If Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 54 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C261 | VILCEK, The cytokines: An overview. In: The Cytokine Handbook, Fourth Ed. M. Lotze and A.W. Thompson (eds.), 2003;1:3-14. | |
| | C262 | VOLHARDT, 18-5. Amides: The Least-Reactive Carboxylic Acid Derivatives. Organic Chemistry. 1987:813. | |
| | C263 | VOLLMER <i>et al.</i> , Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev. 2002 Jun;12(3):165-75. | |
| | C264 | WAGNER <i>et al.</i> , Induction of cytokines in cynomolgus monkeys by the immune response modifiers, imiquimod, S-27609 and S-28463. Cytokine. 1997 Nov;9(11):837-45. | |
| | C265 | WAGNER <i>et al.</i> , Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod. Cellular Immunology. 1999;191:10-19. | |
| | C266 | WANG, Structure and Chemistry of 4-Hydroxy-6-methyl-2-pyridone. J Heterocyclic Chem. 1970;7:389-92. | |
| | C267 | WARREN <i>et al.</i> , Macrophage Growth Factor CSF-1 Stimulates Human Monocyte Production of Interferon, Tumor Necrosis Factor, and Colony Stimulating Activity. J Immunol. 1986;137(7):2281-85. | |
| | C268 | WASSERMAN <i>et al.</i> , Loxoscelism and necrotic arachnidism. J Toxicol Clin Toxicol. 1983-1984;21(4-5):451-72. | |
| | C269 | WEDLOCK <i>et al.</i> , Physiological effects and adjuvanticity of recombinant brushtail possum TNF-alpha. Immunol Cell Biol. 1999 Feb;77(1):28-33. | |
| | C270 | WELLS, Additivity of Mutational Effects in Proteins. Biochemistry. 1990;29(37):8509-17. | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 55 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C271 | WERMUTH, Molecular Variations Based on Isosteric Replacements. Practice of Medicinal Chemistry. 1996:203-37. | |
| | C272 | WEXLER <i>et al.</i> , Accurate identification of experimental pulmonary metastases. J Natl Cancer Inst. 1966 Apr;36(4):641-5. | |
| | C273 | WIBAUT <i>et al.</i> , Syntheses of 3,4-Dimethylpyridine, 2,3-Dimethylpyridine and 2-Methyl-3-Ethylpyridine. Rec Trav Chim. 1944;63:231-38. | |
| | C274 | WIERDA <i>et al.</i> , CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood. 2000 Nov 1;96(9):2917-24. | |
| | C275 | WIESELER-FRANK <i>et al.</i> , Central proinflammatory cytokines and pain enhancement. Neurosignals. 2005;14(4):166-74. | |
| | C276 | WILLIAMS <i>et al.</i> , Grignard Reactions to Chiral Oxazolidine Aldehydes. Tetrahedron. 1996;52:11673-94. | |
| | C277 | WILSON <i>et al.</i> , Spiders and spider bites. Dermatol Clin. 1990 Apr;8(2):277-86. | |
| | C278 | WRIGHT <i>et al.</i> , Clinical presentation and outcome of brown recluse spider bite. Ann Emerg Med. 1997 Jul;30(1):28-32. | |
| | C279 | WU <i>et al.</i> , Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved. J Interferon Cytokine Res. 2001 Dec;21(12):1117-27. | |
| | C280 | YAMAMOTO <i>et al.</i> , Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature. 2002 Nov 21;420(6913):324-9. | |

| | | | |
|--------------------|--------------------|-----------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|--------------------|--------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 56 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C281 | YEUNG-YUE <i>et al.</i> , The management of herpes simplex virus infections. Curr Opin Infect Dis. 2002 Apr;15(2):115-22. | |
| | C282 | YUTILOV <i>et al.</i> , Synthesis and some reactions of 4-nitroimidazo[4-5-c]pyridin-2-ones. CAPLUS English Abstract DN 91:175261. VINITI.1978:1193-78. Abstract Only. | |
| | C283 | ZAGON <i>et al.</i> , Immunoelectron microscopic localization of the opioid growth factor receptor (OGFr) and OGF in the cornea. Brain Res. 2003;967:37-47. | |
| | C284 | ZAGON <i>et al.</i> , Opioids and the apoptotic pathway in human cancer cells. Neuropeptides. 2003;37:79-88. | |
| | C285 | ZAGON <i>et al.</i> , The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev. 2002 Feb;38(3):351-76. Review. | |
| | C286 | ZAGON <i>et al.</i> , The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells. Neuropeptides. 2003 Oct;37(5):290-7. | |
| | C287 | ZAMBON, Periodontal diseases: microbial factors. Ann Periodontol. 1996 Nov;1(1):879-925. | |
| | C288 | ZARUBIN <i>et al.</i> , Theoretical Study of Antagonists and Inhibitors of Mammalian Adenosine Deaminase: I. Adenosine and Its Aza- and Deazaanalogues. Russ J Bioorg Chem. 2002;28(4):284-92. | |
| | C289 | ZHANG <i>et al.</i> , Structural features of azidopyridinyl neonicotinoid probes conferring high affinity and selectivity for mammalian alpha4beta2 and Drosophila nicotinic receptors. J Med Chem. 2002 Jun 20;45(13):2832-40. | |
| | C290 | ZHU <i>et al.</i> , Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. J Leukoc Biol. 2002 Dec;72(6):1154-63. | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|----|----|----|--------------------------|------------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/595,103-Conf. #2609 |
| | | | | Filing Date | February 14, 2006 |
| | | | | First Named Inventor | Kyle J. Lindstrom |
| | | | | Art Unit | 1625 |
| | | | | Examiner Name | N. Rahmani |
| Sheet | 57 | of | 57 | Attorney Docket Number | C1271.70021US02 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | C291 | ZHU <i>et al.</i> , Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. J Leukoc Biol. 2002 Apr;71(4):686-94. | |
| | C292 | ZIEGLER-HEITBROCK <i>et al.</i> , Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood. 1989 May 1;73(6):1426-30. | |
| | C293 | ZYRYANOV <i>et al.</i> , Heterocyclization of 1-(2'-Carbethoxyphenyl)-5-Methyltetrazole. Chemistry of Heterocyclic Compounds. English Edition. 1981;16(12):1286-88. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|--------------------|--------------------|------------|
| Examiner Signature | /Niloofer Rahmani/ | Date Considered | 08/24/2010 |
|-----------------------|--------------------|--------------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NR/